Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On November 18, 2022, Viveve Medical, Inc. (the "Company") received a letter
from The Nasdaq Stock Market LLC ("Nasdaq") indicating that it is not in
compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed
on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in
stockholders' equity for continued listing. In its quarterly report on Form 10-Q
for the quarter ended September 30, 2022 filed with the Securities and Exchange
Commission (the "Commission") on November 10, 2022, the Company reported
stockholders' equity of $1,184,000, and, as a result, does not currently satisfy
Listing Rule 5550(b)(1).
Nasdaq's letter has no immediate impact on the listing of the Company's common
stock, which will continue to be listed and traded on Nasdaq, subject to the
Company's compliance with the other continued listing requirements. Nasdaq's
letter provides the Company 45 calendar days, or until January 3, 2023, to
submit a plan to regain compliance. If the plan is accepted, the Company can be
granted up to 180 calendar days from November 18, 2022, to evidence compliance.
There can be no assurance that the Company will be able to regain compliance
with all applicable continued listing requirements or that its plan will be
accepted by the Nasdaq staff. In the event the plan is not accepted by the
Nasdaq staff, or in the event the plan is granted but the Company fails to
regain compliance within the plan period, the Company would have the right to a
hearing before an independent panel. The hearing request would stay any
suspension or delisting action pending the conclusion of the hearing process and
the expiration of any additional extension period granted by the panel following
the hearing.
The Company intends to take all reasonable measures available to regain
compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. The
Company is currently evaluating its available options to resolve the deficiency
and regain compliance with the Nasdaq minimum stockholders' equity requirement.
The Company intends to submit the compliance plan by the Nasdaq deadline.
As previously disclosed on its current report on Form 8-K filed with the
Commission on June 3, 2022, the Company has also received a letter from Nasdaq
advising the Company that it was not in compliance with Nasdaq Listing Rule
5550(a)(2), which requires the Company to maintain a minimum bid price of at
least $1.00 per share.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
VIVEVE MEDICAL, INC. 
